Interaction of lipoprotein (a) with the extracellular matrix

Fibrinolysis and Proteolysis

Volumn 12, Issue 2, 1998, Pages 79-87

  Miles, L A ^a   Sebald, M T ^a   Fless, G M ^b   Scanu, A M ^b   Curtiss, L K ^a   Plow, E F ^c   Hoover Plow, J L ^c  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c JACOBS ENGINEERING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN A; MATRIGEL;

ARTICLE; ATHEROSCLEROSIS; BASEMENT MEMBRANE; BINDING SITE; EXTRACELLULAR MATRIX; HYDROPHOBICITY; LIPOPROTEIN METABOLISM; MACROPHAGE ACTIVATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; SARCOMA CELL;

EID: 0031746872     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(98)80380-9     Document Type: Article

References (67)

1. Simionescu M, Simionescu N. Proatherosclerotic events: Pathobiochemical changes occurring in the arterial wall before monocyte migration. FASEB J 1993; 7: 1359-1366.
2. Nordestgaard BG. The vascular endothelial barrier-selective retention of lipoproteins. Curr Opin Lipidol 1996; 7: 269-273.
3. Camejo G, Hurt-Camejo E, Olsson U, Bondjers G. Proteoglycans and lipoproteins in atherosclerosis. Curr Opin Lipidol 1993; 4: 385-391.
4. Bostom AG, Gagnon DR, Cupples A et al. A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women. Circulation 1994; 90: 1688-1695.
5. Terres W, Tatsis E, Pfalzer B, Beil FU, Beisiegel U, Hamm CW. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a). Circulation 1995; 91: 948-950.
6. Groves P, Rees A, Bishop A et al. Apolipoprotein(a) concentrations and susceptibility to coronary artery disease in patients with peripheral vascular disease. Br Heart J 1993; 69: 26-30.
7. Fless GM, Rolih CA, Scanu AM. Heterogeneity of human plasma lipoprotein(a): isolation and characterization of the lipoprotein subspecies and their apoproteins. J Biol Chem 1984; 259: 11470-11478.
8. Miles LA, Plow EF. Lp(a): an interloper into the fibrinolytic system? Thromb Haemost 1990; 63: 331-335.
9. Howard GC, Pizzo SV. Biology of disease: lipoprotein(a) and its role in atherothrombotic disease. Lab Invest 1993; 69: 373-386.
10. Scanu AM, Edelstein C. Kringle-dependent structural and functional polymorphism of apolipoprotein(a). Biochim Biophys Acta 1995; 1256: 1-12.
11. Harpel PC, Hermann A, Zhang XX, Ostfeld I, Borth W. Lipoprotein (a) plasmin modulation, and atherogenesis. Thromb Haemost 1995; 74: 382-386.
12. Gushing GL, Gaubatz JW, Nava ML et al. Quantitation and localization of apolipoproteins(a) and B in coronary artery bypass vein grafts resected at reoperation. Arteriosclerosis 1989; 593: 603.
13. Rath M, Niendorf A, Reblin T, Dietel M, Krebber H-J, Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989; 9: 579-592.
14. Eaton DL, Fless GM, Kohr WJ et al. Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc Natl Acad Sci USA 1987; 84: 3224-3228.
15. McLean JW, Tomlinson JE, Kuang W-J et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330: 132-137.
16. 37. J Clin Invest 1993; 91: 283-291.
17. Ezratty A, Simon DI, Loscalzo J. Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation. Biochemistry 1993; 32: 4628-4633.
18. Plow EF, Herren T, Redlitz A, Miles LA, Hoover-Plow JL. The cell biology of the plasminogen system. FASEB J 1995; 9: 939-945.
19. Miles LA, Fless GM, Scanu AM et al. Interaction of Lp(a) with plasminogen binding sites on cells. Thromb Haemost 1995; 73: 458-465.
20. Wiman B, Lijnen HR, Collen D. On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha-2-antiplasmin and in fibrinogen. Biochim Biophys Acta 1979; 579: 142-154.
21. Lucas MA, Fretto LJ, McKee PA. The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem 1983; 258: 4249-4256.
22. Kluft C, Jie AFH, Los P, deWit E, Havekes L. Functional analogy between lipoprotein(a) and plasminogen in the binding to the kringle 4 binding protein, tetranectin. Biochem Biophys Res Commun 1989; 161: 427-433.
23. Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA 1989; 86: 3847-3851.
24. Fleury V, Angles-Cano E. Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines. Biochemistry 1991; 30: 7630-7638.
25. Leerink CB, Duif PFCCM, Gimpel JA, Kortlandt W, Bouma BN, van Rijn HJM. Lysine-binding heterogeneity of Lp(a): consequences for fibrin binding and inhibition of plasminogen activation. Thromb Haemost 1992; 68: 185-188.
26. Edelberg JM, Gonzalez-Gronow M, Pizzo SV. Lipoprotein(a) inhibits streptokinase-mediated activation of human plasminogen. Biochemistry 1989; 28: 2370-2374.
27. Edelberg JM, Gonzalez-Gronow M, Pizzo SV. Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator. Thromb Res 1990; 57: 155-162.
28. Hoover-Plow JL, Miles LA, Fless GM, Scanu AM, Plow EF. Comparison of the lysine binding functions of lipoprotein(a) and plasminogen. Biochemistry 1993; 32: 13681-13687
29. Snyder ML, Polacek D, Scanu AM, Fless GM. Comparative binding and degradation of lipoprotein(a) and low density lipoprotein by human monocyte derived macrophages. J Biol Chem 1992; 267: 339-346.
30. Curtiss LK, Edgington TS. Immunochemical heterogeneity of human plasma high density lipoproteins. J Biol Chem 1985; 260: 2982-2993.
31. Shepherd J, Bedford DK, Morgan HG. Radiodination of human low density lipoprotein: a comparison of four methods. Clin Chim Acta 1976; 66: 97-109.
32. Deutsch DG, Mertz ET, Plasminogen: purification from human plasma by affinity chromatography. Science 1970; 170: 1095-1096.
33. Miles LA, Dahlberg CM, Plow EF. The cell-binding domains of plasminogen and their function in plasma. J Biol Chem 1988; 263: 11928-11934.
34. Wallen P, Wiman B. Characterization of human plasminogen II. Separation and partial characterization of different molecular forms of human plasminogen. Biochim Biophys Acta 1972; 257: 122-134.
35. Miles LA, Plow EF. Binding and activation of plasminogen on the platelet surface. J Biol Chem 1985; 260: 4303-4311.
36. Munson PJ, Rodbard D. Ligand a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 1980; 107: 220-239.
37. Orkin RW, Gehron P, McGoodwin EB, Martin GR, Valantine T, Swarm R. A murine tumor producing matrix of basement membrane. J Exp Med 1977; 145: 204-220.
38. Albini A, Iwamoto Y, Kleinman HK, Matrin GR, Aaronson SA, Kozlowski JM, McEwan RN. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987; 47: 3239-3245.
39. Kleinman HK, McGarvey ML, Hassell JR, Star VL, Cannon FB, Laune GW, Martin GR. Basement membrane complexes with biological activity. Biochemistry 1986; 25: 312-318.
40. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodelling. Trends Genet 1990; 6: 121-125.
41. Schnaper WH, Grant DS, Stetler-Stevenson WG et al. Type IV collagenases and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol 1993; 156: 235-246.
42. Iverius P-H. The interaction between human plasma lipoproteins and connective tissues glycosaminoglycans. J Biol Chem 1972; 247: 2606-2613.
43. Saxena U, Klein MG, Vanni TM, Goldberg IJ. Lipoprotein lipase increases low density lipoprotein retention by subendothelial cell matrix. J Clin Invest 1992; 89: 373-380.
44. McConathy WJ. Interactions of Lp(a) with subendothelial cell matrix. In: Stein O, Eisenberg S, Stein Y (eds). Proceedings of the Ninth International Symposium on Atherosclerosis, 1991: 119.
45. Kramer-Guth A, Greiber S, Pavenstadt H, Quaschning T, Winkler K, Schollmeyer P, Wanner C. Interaction of native and oxidized lipoprotein(a) with human mesangial cells and matrix. Kidney Int 1996; 49: 1250-1261.
46. Edelstein C, Mandala M, Pfaffinger D, Scanu AM. Determinants of lipoprotein(a) assembly: A study of wild-type and mutant apolipoprotein(a) phenotypes isolated from human and rhesus monkey lipoprotein(a) under mild reductive conditions. Biochemistry 1995; 34: 16483-16492.
47. Gabel BR, May LF, Marcovina SM, Koschinsky ML. Lipoprotein(a) assembly: Quantitative assessment of the role of apo(a) kringle IV types 2-10 in particle formation. Arterioscler Thromb Vasc Biol 1996; 16: 1559-1567
48. Trieu VN, McConathy WJ. A two-step model for lipoprotein(a) formation. J Biol Chem 1995; 270: 15471-15474.
49. Niemann MA, Baggott JE, Miller EJ. Binding of SPAAT, the 44-residue C-terminal peptide of alpha 1-antitrypsin, to proteins of the extracellular matrix. J Cell Biochem 1997; 66: 346-357.
50. Caceres J, Brandan E. Interaction between Alzheimer's disease beta A4 precursor protein (APP) and the extracellular matrix: evidence for the participation of heparan sulfate proteoglycans. J Cell Biochem 1997; 65: 145-158.
51. Malinda KM, Goldstein AL, Kleinman HK. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J 1997; 11: 474-481.
52. Yamagishi S, Yonekura H, Yamamoto Y et al. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chem 1997; 272: 8723-8730.
53. Holst-Hansen C, Johannessen B, Hoyer-Hansen G, Romer J, Ellis V, Brunner N. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis 1996; 14: 297-307.
54. Klausen IC, Sjol A, Hansen PS et al. Apolipoprotein(a) isoforms and coronary heart disease in men: a nested case-control study. Atherosclerosis 1997; 132: 77-84.
55. Rang C, Durlach V, Soulat T, Fournier C, Anglés-Cano E. Lipoprotein (a) isoforms display differences in affinity for plasminogen-like binding to human mononuclear cells. Arterioscler Thromb Vasc Biol 1997; 17: 2036-2043.
56. 2-macroglobulin receptor. FEBS Lett 1993; 325: 271-275.
57. Sangrar W, Gabel BR, Boffa MB et al. The solution phase interaction between apolipoprotein(a) and plasminogen inhibits the binding of plasminogen to a plasmin-modified fibrinogen surface. Biochemistry 1997; 36: 10353-10363.
58. Markus G, De Pasquale JL, Wissler FC. Quantitative determination of the binding of epsilon-aminocaproic acid to native plasminogen. J Biol Chem 1982; 253: 727-732.
59. Lerch PG, Rickli EE. Studies on the chemical nature of lysine-binding sites and on their localization in human plasminogen. Biochim Biophys Acta 1980; 625: 374-378.
60. Ernst A, Helmhold M, Brunner C, Pethö-Schramm A, Armstrong VW, Müller H-J, Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a). J Biol Chem 1995; 270: 6227-6234.
61. Trieu VN, Zioncheck TF, Lawn RM, McConathy WJ. Interaction of apo-lipoprotein(a) with apolipoprotein B- containing lipoproteins. J Biol Chem 1991; 256: 4778-4782.
62. Salonen E-M, Jauhiainen M, Zardi L, Vaheri A, Ehnholm C. Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it. EMBO J 1989; 8: 4035-4040.
63. Van der Hoek YY, Sangrar W, Côté GP, Kastelein JJP, Koschinsky ML. Binding of recombinant apolipoprotein(a) to extracellular matrix proteins. Arterioscler Thromb 1994; 14: 1792-1798.
64. Edelstein C, Italia JA, Klezovitch O, Scanu AM. Functional and metabolic differences between elastase-generated fragments of human lipoprotein[a] and apolipoprotein[a]. J Lipid Res 1996; 37: 1786-1801.
65. Pekelharing HLM, Kleinveld HA, Duif PFCCM, Bouma BN, van Rijn HJM. Effect of lipoprotein(a) and LDL on plasminogen binding to extracellular matrix and a matrix-dependent plasminogen activation by tissue plasminogen activator. Thromb Haemost 1996; 75: 497-502.
66. Ernst E. Fibrinogen: an important risk factor for atherothrombotic diseases. Ann Med 1994; 26: 15-22.
67. Lawn RM, Pearle AD, Kunz LL, Rubin EM, Reckless J, Metcalfe JC, Grainger DJ. Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice. J Biol Chem 1996; 217: 31367-31371.